Register for our free email digests:
Vanda Pharmaceuticals Inc.
www.vandapharma.com
Latest From Vanda Pharmaceuticals Inc.
Supreme Court Takes Pass on Clarifying Patent Eligibility, Disappointing BioPharma
Industry now needs to wait for a more appealing appeal or a revived legislative effort after the high court declines review of Athena Diagnostics v. Mayo Collaborative Services, which created a sharp divide in the Federal Circuit, and Hikma v. Vanda; biopharma and others contend eligibility issue is biggest problem in patent system.
Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen
Vanda Not Ready To Give Up On Jet Lag Indication For Hetlioz Despite CRL
Complete response letter follows July deficiencies letter that made approval seem highly unlikely. Vanda called the setback perplexing and said it plans to continue working to get jet lag disorder added to the Hetlioz label.
Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon
The latest drug development news and highlights from our US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Dermatology
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Vanda Pharmaceuticals Inc.
- Senior Management
-
Mihael H Polymeropoulos, MD, Pres. & CEO
James Kelly, EVP, CFO & Treasurer
Gunther Birznieks, SVP, Bus. Dev.
Deepak Phadke, PhD, VP, Manufacturing
Gian Piero Reverberi, SVP, Chief Commercial Officer - Contact Info
-
Vanda Pharmaceuticals Inc.
Phone: (202) 734-3400
2200 Pennsylvania Ave. NW
Ste. 300E
Washington, DC 20037
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice